NCT01522807 - A Study Of Three PF-05190457 Formulations In Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state

Trial Locations (1)

Pfizer Investigational Site, Singapore